SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) has begun its detailed technical review of SHINE’s application to operate the medical isotope production facility the company is building in Janesville, Wis.
SHINE Medical Technologies today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.
SHINE Medical Technologies LLC today announced the closing of a $50-million financing with funds managed by Oaktree Capital Management L.P. (“Oaktree”), a leading global investment firm with more than $120 billion under management as of June 30, 2019.
Phoenix and SHINE Achieve New World Record for Strongest Nuclear Fusion Reaction in a Steady-State System. Leading nuclear technology companies collaborating to help turn nuclear weapons into medicine and help a billion patients. Breakthrough has potential to transform medical isotope production, solve a global health care shortage, provide a stepping stone to cleaner, safer, more abundant energy
SHINE Medical Technologies LLC, today announced that it is holding its second annual design competition in collaboration with the School District of Janesville. The competition asks students to create a 3D-printed object to be used by SHINE as an employee award of excellence, titled The Illuminator Award.
Founder and CEO Greg Piefer has received the University of Wisconsin-Madison Department of Physics’ 2019 Distinguished Alumni Award. The award is the highest honor presented to accomplished graduates of UW-Madison for their professional achievements, contributions to society and support of the university.
SHINE Medical Technologies LLC today announced the appointment of Harrie Buurlage as vice president, European operations. Mr. Buurlage will oversee all of SHINE’s activities in Europe, including the company’s siting, construction and operation of a medical isotope production facility there.
SHINE Medical Technologies LLC today announced it has received a $15-million award from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA). The award was made by the agency as part of its effort to establish a reliable, U.S.-produced supply of molybdenum-99 (Mo-99), the most commonly used medical isotope.
SHINE Medical Technologies LLC today announced that its team for the annual Bert Blain Memorial Heart Walk in Janesville last weekend exceeded its fundraising goal by 40 percent. The SHINE team’s goal was $6,000 and it raised more than $8,400 to support the American Heart Association’s mission of reducing disability and death caused by heart disease and stroke.
SHINE Medical Technologies, LLC today announced the appointment of Paul D. Ryan to the company’s board of directors.